S&P 500   3,892.64 (-0.21%)
DOW   31,198.89 (-0.17%)
QQQ   286.28 (-1.14%)
AAPL   136.38 (-0.71%)
MSFT   250.13 (-1.19%)
FB   192.48 (+0.62%)
GOOGL   2,161.83 (-2.08%)
AMZN   2,141.45 (-0.23%)
TSLA   652.22 (-8.06%)
NVDA   164.07 (-4.19%)
BABA   86.63 (-1.21%)
NIO   16.23 (-2.58%)
AMD   92.09 (-4.74%)
CGC   5.48 (-6.64%)
MU   68.23 (-1.69%)
T   20.30 (+0.45%)
GE   74.94 (-1.06%)
F   12.44 (-3.19%)
DIS   101.84 (-1.26%)
AMC   11.83 (-9.56%)
PFE   52.28 (+3.22%)
PYPL   80.24 (-1.28%)
NFLX   184.52 (+0.57%)
S&P 500   3,892.64 (-0.21%)
DOW   31,198.89 (-0.17%)
QQQ   286.28 (-1.14%)
AAPL   136.38 (-0.71%)
MSFT   250.13 (-1.19%)
FB   192.48 (+0.62%)
GOOGL   2,161.83 (-2.08%)
AMZN   2,141.45 (-0.23%)
TSLA   652.22 (-8.06%)
NVDA   164.07 (-4.19%)
BABA   86.63 (-1.21%)
NIO   16.23 (-2.58%)
AMD   92.09 (-4.74%)
CGC   5.48 (-6.64%)
MU   68.23 (-1.69%)
T   20.30 (+0.45%)
GE   74.94 (-1.06%)
F   12.44 (-3.19%)
DIS   101.84 (-1.26%)
AMC   11.83 (-9.56%)
PFE   52.28 (+3.22%)
PYPL   80.24 (-1.28%)
NFLX   184.52 (+0.57%)
S&P 500   3,892.64 (-0.21%)
DOW   31,198.89 (-0.17%)
QQQ   286.28 (-1.14%)
AAPL   136.38 (-0.71%)
MSFT   250.13 (-1.19%)
FB   192.48 (+0.62%)
GOOGL   2,161.83 (-2.08%)
AMZN   2,141.45 (-0.23%)
TSLA   652.22 (-8.06%)
NVDA   164.07 (-4.19%)
BABA   86.63 (-1.21%)
NIO   16.23 (-2.58%)
AMD   92.09 (-4.74%)
CGC   5.48 (-6.64%)
MU   68.23 (-1.69%)
T   20.30 (+0.45%)
GE   74.94 (-1.06%)
F   12.44 (-3.19%)
DIS   101.84 (-1.26%)
AMC   11.83 (-9.56%)
PFE   52.28 (+3.22%)
PYPL   80.24 (-1.28%)
NFLX   184.52 (+0.57%)
S&P 500   3,892.64 (-0.21%)
DOW   31,198.89 (-0.17%)
QQQ   286.28 (-1.14%)
AAPL   136.38 (-0.71%)
MSFT   250.13 (-1.19%)
FB   192.48 (+0.62%)
GOOGL   2,161.83 (-2.08%)
AMZN   2,141.45 (-0.23%)
TSLA   652.22 (-8.06%)
NVDA   164.07 (-4.19%)
BABA   86.63 (-1.21%)
NIO   16.23 (-2.58%)
AMD   92.09 (-4.74%)
CGC   5.48 (-6.64%)
MU   68.23 (-1.69%)
T   20.30 (+0.45%)
GE   74.94 (-1.06%)
F   12.44 (-3.19%)
DIS   101.84 (-1.26%)
AMC   11.83 (-9.56%)
PFE   52.28 (+3.22%)
PYPL   80.24 (-1.28%)
NFLX   184.52 (+0.57%)
NASDAQ:VYNE

VYNE Therapeutics (VYNE) Stock Forecast, Price & News

$0.39
-0.01 (-2.50%)
(As of 05/20/2022 03:21 PM ET)
Add
Compare
Today's Range
$0.38
$0.41
50-Day Range
$0.37
$0.75
52-Week Range
$0.34
$4.24
Volume
4,100 shs
Average Volume
434,180 shs
Market Capitalization
$22.58 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.11
30 days | 90 days | 365 days | Advanced Chart
Receive VYNE News and Ratings via Email

Sign-up to receive the latest news and ratings for VYNE Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

VYNE Therapeutics logo

About VYNE Therapeutics

VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VYNE
Fax
N/A
Employees
28
Year Founded
N/A

Sales & Book Value

Annual Sales
$14.76 million
Book Value
$0.96 per share

Profitability

Net Income
$-73.33 million
Net Margins
-444.88%
Pretax Margin
-662.06%

Debt

Price-To-Earnings

Miscellaneous

Free Float
56,287,000
Market Cap
$22.58 million
Optionable
Not Optionable

Company Calendar

Last Earnings
3/17/2022
Today
5/20/2022
Next Earnings (Estimated)
8/11/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

1.54 out of 5 stars

Medical Sector

1010th out of 1,420 stocks

Pharmaceutical Preparations Industry

500th out of 679 stocks

Analyst Opinion: 3.5Community Rank: 3.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -













VYNE Therapeutics (NASDAQ:VYNE) Frequently Asked Questions

Is VYNE Therapeutics a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for VYNE Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" VYNE Therapeutics stock.
View analyst ratings for VYNE Therapeutics
or view top-rated stocks.

When is VYNE Therapeutics' next earnings date?

VYNE Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our earnings forecast for VYNE Therapeutics
.

How were VYNE Therapeutics' earnings last quarter?

VYNE Therapeutics Inc. (NASDAQ:VYNE) issued its quarterly earnings results on Thursday, March, 17th. The company reported ($0.22) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.22). The firm had revenue of $2.29 million for the quarter, compared to the consensus estimate of $4.09 million. VYNE Therapeutics had a negative net margin of 444.88% and a negative trailing twelve-month return on equity of 103.25%.
View VYNE Therapeutics' earnings history
.

When did VYNE Therapeutics' stock split? How did VYNE Therapeutics' stock split work?

VYNE Therapeutics's stock reverse split on the morning of Tuesday, February 16th 2021. The 1-4 reverse split was announced on Thursday, February 11th 2021. The number of shares owned by shareholders was adjusted after the market closes on Monday, February 15th 2021. An investor that had 100 shares of VYNE Therapeutics stock prior to the reverse split would have 25 shares after the split.

What price target have analysts set for VYNE?

3 brokerages have issued 12-month target prices for VYNE Therapeutics' shares. Their forecasts range from $6.00 to $7.00. On average, they anticipate VYNE Therapeutics' share price to reach $6.50 in the next year. This suggests a possible upside of 1,566.7% from the stock's current price.
View analysts' price targets for VYNE Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are VYNE Therapeutics' key executives?
VYNE Therapeutics' management team includes the following people:
  • Mr. David T. Domzalski, CEO, Pres & Director (Age 55, Pay $892.07k)
  • Dr. Iain A. Stuart Ph.D., Chief Scientific Officer (Age 49, Pay $534.8k)
  • Ms. Mutya Harsch J.D., Gen. Counsel, Chief Legal Officer & Company Sec. (Age 47, Pay $559.54k)
  • Mr. Tyler Zeronda, CFO, Principal Accounting Officer & Treasurer (Age 36)
  • Mr. Raymond G. Steitz, Sr. VP of Global HR (Age 63)
  • Dr. Russell Elliott D.Phil., Sr. VP of Pharmaceutical Devel. (Age 56)
  • Dr. Darrell S. Rigel M.S., M.D., MS, Consultant (Age 72)
What other stocks do shareholders of VYNE Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other VYNE Therapeutics investors own include Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Novan (NOVN), OrganiGram (OGI), Zosano Pharma (ZSAN), KushCo (KSHB), Bionano Genomics (BNGO), Pennsylvania Real Estate Investment Trust (PEI), Sorrento Therapeutics (SRNE) and Aeterna Zentaris (AEZS).

What is VYNE Therapeutics' stock symbol?

VYNE Therapeutics trades on the NASDAQ under the ticker symbol "VYNE."

Who are VYNE Therapeutics' major shareholders?

VYNE Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (2.63%), Renaissance Technologies LLC (1.72%), State Street Corp (0.36%), Bailard Inc. (0.25%), Beacon Pointe Advisors LLC (0.13%) and Mackenzie Financial Corp (0.12%). Company insiders that own VYNE Therapeutics stock include Andrew Saik, David Domzalski, Patrick G Lepore and Perceptive Advisors Llc.
View institutional ownership trends for VYNE Therapeutics
.

Which major investors are selling VYNE Therapeutics stock?

VYNE stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., and State Street Corp.
View insider buying and selling activity for VYNE Therapeutics
or view top insider-selling stocks.

Which major investors are buying VYNE Therapeutics stock?

VYNE stock was bought by a variety of institutional investors in the last quarter, including Bailard Inc., Beacon Pointe Advisors LLC, Mackenzie Financial Corp, and Renaissance Technologies LLC. Company insiders that have bought VYNE Therapeutics stock in the last two years include Andrew Saik, David Domzalski, Patrick G Lepore, and Perceptive Advisors Llc.
View insider buying and selling activity for VYNE Therapeutics
or or view top insider-buying stocks.

How do I buy shares of VYNE Therapeutics?

Shares of VYNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is VYNE Therapeutics' stock price today?

One share of VYNE stock can currently be purchased for approximately $0.39.

How much money does VYNE Therapeutics make?

VYNE Therapeutics has a market capitalization of $22.58 million and generates $14.76 million in revenue each year. The company earns $-73.33 million in net income (profit) each year or ($0.94) on an earnings per share basis.

How many employees does VYNE Therapeutics have?

VYNE Therapeutics employs 28 workers across the globe.

What is VYNE Therapeutics' official website?

The official website for VYNE Therapeutics is www.menlotherapeutics.com.

How can I contact VYNE Therapeutics?

VYNE Therapeutics' mailing address is 520 U.S. HIGHWAY 22 SUITE 204, BRIDGEWATER NJ, 08807. The company can be reached via phone at (800) 755-7936 or via email at [email protected].

This page was last updated on 5/20/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.